Skip to main content
. 2015 Oct 21;6(38):41383–41397. doi: 10.18632/oncotarget.5510

Table 1. Correlation between the clinicopathologic variables and SPC24 in HCC.

Clinical character Variable No.of patients SPC24 χ2 p-value
low n (%) high n (%)
Age (years) ≤60 167 44 (26.3) 123 (73.7) 0.116 0.733
>60 45 13 (28.9) 32 (71.1)
Gender Female 31 8 (25.8) 23 (74.2) 0.022 0.883
Male 181 49 (27.1) 132 (72.9)
Family history No 177 44 (24.9) 133 (75.1) 2.243 0.134
Yes 35 13 (37.1) 22 (62.9)
Wine-drinking No 100 24 (24.0) 76 (76.0) 0.802 0.370
Yes 112 33 (29.5) 79 (70.5)
HBsAg Negative 37 8 (21.6) 29 (78.4) 0.632 0.427
Positive 175 49 (28.0) 126 (72.0)
AFP (μg/l) ≤200 95 32 (33.7) 63 (66.3) 4.046 0.044
>200 117 25 (21.4) 92 (78.6)
Median size (cm) ≤5 52 20 (38.5) 32 (61.5) 4.696 0.030
>5 160 37 (23.1) 123 (76.9)
Cirrhosis No 20 7 (35.0) 13 (65.0) 0.739 0.390
Yes 192 50 (26.0) 142 (74.0)
Tumor number Single 145 46 (31.7) 99 (68.3) 5.461 0.019
Multiple 67 11 (16.4) 56 (83.6)
BCLC stage 0-A 101 35 (34.7) 66 (65.3) 5.919 0.015
B–C 111 22 (19.8) 89 (80.2)
PVTT No 166 46 (27.7) 120 (72.3) 0.264 0.607
Yes 46 11 (23.9) 35 (76.1)
Distant metastasis No 193 51 (26.4) 142 (73.6) 0.234 0.629
Yes 19 6 (31.6) 13 (68.4)
Recurrence No 145 41 (28.3) 104 (71.7) 0.450 0.502
Yes 67 16 (23.9) 51 (76.1)

Abbreviations: HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein; BCLC, Barcelona clinic liver cancer; PVTT, portal vein tumor thrombus.